G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to ...

The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to $94.31 / share. This is an increase of 21.89% from the prior estimate of $77.

Shares of Structure Therapeutics are soaring Monday after the company reported positive topline data from a weight loss drug trial.

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ...

The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity. The study will ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

Scientists reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands. Through an international collaboration, scientists at St. Jude ...

Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...